CD44 and ovarian carcinoma: On the other hand, further experimental validations are also needed to prove the interactions among FBXL7, PDGF and CD44 in conferring ovarian cancer with PTX resistance, even though the in silico analysis significantly predicted the activations of these signal transducers in the PTX-resistant ovarian cancer cells.